A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors (Q38926282)
Jump to navigation
Jump to search
scientific article published on 6 March 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors |
scientific article published on 6 March 2017 |
Statements
1 reference
A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors (English)
1 reference
Susan M Domchek
1 reference
Ronnie Shapira-Frommer
1 reference
Rebecca Kristeleit
1 reference
Geoffrey I Shapiro
1 reference
Howard A Burris
1 reference
Amit M Oza
1 reference
Patricia LoRusso
1 reference
Manish R Patel
1 reference
Yvette Drew
1 reference
Lee-May Chen
1 reference
Tamar Safra
1 reference
Ana Montes
1 reference
Heidi Giordano
1 reference
Lara Maloney
1 reference
Sandra Goble
1 reference
Jim Xiao
1 reference
Jen Borrow
1 reference
Lindsey Rolfe
1 reference
6 March 2017
1 reference
1 reference
23
1 reference
15
1 reference
4095-4106
1 reference
Identifiers
1 reference
1 reference